STOCK TITAN

Pulmonx Corporation - $LUNG STOCK NEWS

Welcome to our dedicated page for Pulmonx Corporation news (Ticker: $LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pulmonx Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pulmonx Corporation's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.37%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences earnings
Pulmonx Corporation

Nasdaq:LUNG

LUNG Rankings

LUNG Stock Data

349.34M
36.98M
4.17%
92.86%
2.9%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY

About LUNG

pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. the company’s first commercial products address emphysema, a form of copd (chronic obstructive pulmonary disease) and the largest unmet medical need in pulmonology. with emphysema, breathing becomes increasingly more difficult as the disease progresses. today in the u.s., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. pulmonx has developed the zephyr endobronchial valve (ebv) therapy, a non-surgical, investigational approach to treating emphysema. the minimally invasive zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. no surgery is involved in the simp